NCT01730378View on ClinicalTrials.gov

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

PHASE4CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

December 5, 2012

Primary Completion Date

December 17, 2013

Study Completion Date

December 17, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Prepandrix™

2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).

BIOLOGICAL

Fluarix™

1 dose administered intramuscularly in the deltoid region of non-dominant arm.

Trial Locations (4)

152703

GSK Investigational Site, Guro Gu

442-723

GSK Investigational Site, Gyeonggi-do

400-711

GSK Investigational Site, Incheon

150-950

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY